Phase II study of flutamide in patients
✍
Daniele J. Perrault; Diane M. Logan; David J. Stewart; Vivien H. C. Bramwell; Al
📂
Article
📅
1988
🏛
Springer US
🌐
English
⚖ 271 KB
The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of the oral antiandrogen flutamide in 33 patients with metastatic breast cancer. Eight patients had received no prior systemic therapy for their metastatic disease and 13 had only one site of metastasis.